DaVita Inc
NYSE:DVA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
99.26
165.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
DaVita Inc
DaVita Inc
Cost of Revenue
DaVita Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DaVita Inc
NYSE:DVA
|
Cost of Revenue
-$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Chemed Corp
NYSE:CHE
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cost of Revenue
-$6.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cost of Revenue
-$316.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
Cigna Corp
NYSE:CI
|
Cost of Revenue
-$206.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cost of Revenue
-$9.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
DaVita Inc
Glance View
DaVita Inc. has emerged as a leading healthcare provider specializing in kidney care, operating over 2,800 outpatient dialysis centers across the United States and 10 additional countries. Founded in 1994, the company has made significant strides in enhancing the quality of life for individuals battling chronic kidney disease. With a mission deeply rooted in patient care, DaVita focuses on delivering comprehensive treatment and support, ensuring that patients receive not only dialysis services but also vital education and resources for managing their condition. This commitment to patient-centric care has positioned DaVita as a notable player in the burgeoning healthcare sector, making it an attractive investment opportunity for those interested in the resilience and growth potential within the industry. From an investor's perspective, DaVita represents a blend of stability and growth potential, driven by an aging population that increasingly requires kidney care services. The company benefits from a favorable reimbursement landscape and has implemented operational efficiencies that enhance profitability. In recent years, DaVita has also ventured into value-based care initiatives, which align incentives towards improved patient outcomes rather than volume. This strategic pivot not only secures a sustainable revenue model but also highlights the company’s adaptability in a rapidly changing healthcare environment. As such, DaVita stands out in the investment community, offering a chance to capitalize on a vital sector poised for expansion, all while contributing to the well-being of countless patients.
See Also
What is DaVita Inc's Cost of Revenue?
Cost of Revenue
-8.5B
USD
Based on the financial report for Sep 30, 2024, DaVita Inc's Cost of Revenue amounts to -8.5B USD.
What is DaVita Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
0%
Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for DaVita Inc have been -2% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
